Who are Crescendo Biologics's investors?

Crescendo Biologics's investors include Andera Partners, Quan Capital, Sofinnova Partners, Astellas Venture Management LLC, EMBL Ventures, Future Planet Capital, Avlar BioVentures, IP Group and 2 more.

Crescendo Biologics

12 known investors

Find your way into Crescendo Biologics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Crescendo Biologics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology. The company collaborates with major pharmaceutical partners including BioNTech and Takeda on drug discovery and development.

Biotech Healthtech Medical Devices

Investors · 12

Andera Partners✓ confirmed by Crescendo BiologicsParis

How we know: the company's own site · funding news · fiercebiotech.com · Not right? Tell us

Quan Capital✓ confirmed by Crescendo BiologicsShanghai

How we know: the company's own site · funding news · fiercebiotech.com · Not right? Tell us

Sofinnova Partners✓ confirmed by Crescendo BiologicsParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · the company's own site · funding news · fiercebiotech.com · open dataset · 5k.vc investor directory · Not right? Tell us

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

How we know: Astellas Venture Management LLC's portfolio page · funding news · prnewswire.com · Not right? Tell us

EMBL Ventureslisted by EMBL VenturesHeidelberg · $108K – $5.4M

How we know: EMBL Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Future Planet Capitallisted by Future Planet CapitalLondon

How we know: Future Planet Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Avlar BioVenturesreportedMadingley

How we know: funding news · Not right? Tell us

IP GroupreportedLondon

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Kreos CapitalreportedLondon

How we know: funding news · press coverage · Not right? Tell us

Takeda VenturesreportedCambridge · $1M – $5M

How we know: fiercebiotech.com · Not right? Tell us

Also in the syndicate · 2

BioNTechImperial Innovationslead

Funding

SEC filings, press & company announcements

Undisclosed amountSeries ADec 2013
Imperial Innovations (lead), Astellas Venture Management, Sofinnova Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing - BioSpacebiospace.com · Apr 2018

Crescendo Biologics Raises £17.5M ($28M) in Series A Financingprnewswire.com · Dec 2013

Frequently asked questions

What does Crescendo Biologics do?: Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology. The company collaborates with major pharmaceutical partners including BioNTech and Takeda on drug discovery and development.
Who are Crescendo Biologics's investors?: Crescendo Biologics's investors include Andera Partners, Quan Capital, Sofinnova Partners, Astellas Venture Management LLC, EMBL Ventures, Future Planet Capital, Avlar BioVentures, IP Group and 2 more.